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ABSTRACT
The release of soluble ligands of activating Natural Killer (NK) cell receptors may represent a regulatory
mechanism of NK cell function both in physiologic and in pathologic conditions. Here, we identified the
extracellular matrix protein Nidogen-1 (NID1) as a ligand of NKp44, an important activating receptor
expressed by activated NK cells. When released as soluble molecule, NID1 regulates NK cell function by
modulating NKp44-induced IFN-γ production or cytotoxicity. In particular, it also modulates IFN-γ
production induced by Platelet-Derived Growth Factor (PDGF)-DD following NKp44 engagement. We
also show that NID1 may be present at the cell surface. In this form or when bound to a solid support
(bNID1), NID1 fails to induce NK cell cytotoxicity or cytokine release. However, analysis by mass spectro-
metry revealed that exposure to bNID1 can induce in human NK cells relevant changes in the proteomic
profiles suggesting an effect on different biological processes.
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Introduction
NK cells are Innate Lymphoid Cells (ILCs) involved in various
immune processes ranging from the direct elimination of
pathogens or tumor cells to the release of cytokines and
chemokines and to regulatory interactions with different
immune cells.1-9 In order to fulfill this variety of functions,
NK cells use an array of receptors which sense microenviron-
mental stimuli and mediate appropriate responses.3,10,11
Several NK receptors are capable of regulating different NK
cell functions. For example, the Natural Cytotoxicity
Receptors (NCRs) NKp46, NKp30, and NKp44, play an
important role in human NK cell-mediated recognition and
killing of virally infected and tumor cells, and also induce the
release of a number of cytokines and chemotactic factors.10,12
In addition, NKp30 and NKp46 mediate regulatory interac-
tions occurring between NK and different leukocytes, includ-
ing dendritic cells (DCs), neutrophils, eosinophils,
macrophages, and T cells.5-9 NCRs were identified and mole-
cularly characterized in ‘90s.13-15 Since then, numerous stu-
dies attempted to identify their ligands. This information is
crucial for a better exploitation of the NK cell potential in the
therapy of tumors, infections, or immune-mediated diseases.-
16-21 In spite of many efforts, so far, the panel of the NCR
ligands has been only partially defined.10,12,22 A reason of
these difficulties is related to the fact that study models of
receptor-ligand interaction for the NCR are rather limited, as
only NKp46 is expressed also on NK cells of rat and mouse.
Moreover, although the NCRs belong to the Ig superfamily,
they greatly differ in their molecular structure, implying that
their ligands may be rather heterogeneous. In addition, each
NCR may interact with different ligands, not necessarily dis-
playing similar molecular features. Thus, for example, NKp46
and NKp44 have been shown to bind viral hemagglutinins.23
On the other hand, molecularly unrelated cellular ligands
have been shown to bind NKp30 (B7H6 and BAT3/BAG6)
and NKp44 (21spe-MLL5).24-26
To further complicate this issue, NCRs may interact with
ligands by different modalities and even opposite functional
outcomes. For example, NKp44 appears to differently mod-
ulate NK cell function by cis- or trans-interactions with
heparan-sulphate proteoglycans (present at the NK or target
cell surface).27,28 In addition, this receptor has been reported
to transduce inhibitory signals upon interaction with
Proliferating Cell Nuclear Antigen (PCNA).29,30 NKp30 trig-
gers cytotoxicity and cytokine release upon binding B7H6 or
BAT3 at the cell surface.24,25,31 Besides NCRs, other activating
receptors, including NKG2D and DNAM-1, contribute to
trigger the NK cell-mediated cytotoxicity.32-34 Ligands specific
for these receptors have been extensively characterized:
MICA/B and ULBPs molecules are recognized by NKG2D,
while PVR and Nectin-2 (belonging to the Nectin family), are
ligands for DNAM-1.32,33,35,36
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Binding to soluble ligands may in some instances inhibit
the triggering capability of activating NK receptors. In these
cases, the release of such ligands in the extracellular environ-
ment may represent an effective mechanism to dampen NK
cell function, not only in physiologic immune interactions but
also in tumor-driven escape strategies.37-40 In this context,
soluble ligands, endowed with suppressive capability, have
been described for NKG2D and DNAM-1 activating receptors
(sMICA, sULBPs, and sPVR) and for NKp30 (sB7H6 and
sBAT3/BAG6).32,33,35,41-50 On the other hand, extracellular
ligands for NKp46 and NKp44 have been recently identified
and demonstrated to have a positive effect on the NK cell
function. NKp46 has been shown to bind an extracellular
molecule: the Complement Factor P (CFP or properdin).51
Recognition of CFP has been indicated as an important tool
for innate responses to pathogens. Regarding NKp44, this
receptor was recently shown to recognize a soluble factor,
namely PDGF-DD. NKp44 engagement by PDGF-DD
resulted in NK cell-mediated release of IFN-γ, TNF-α, and
other proinflammatory cytokines and chemokines.52
In this study, we provide evidence that NKp44 recognizes a
novel extracellular ligand, namely the Nidogen-1 (NID1) pro-
tein (also known as Entactin). We show that the NKp44/NID1
interaction results in a reduced NKp44-mediated induction of
cytokine release by NK cells. Further analysis of the proteomic
changes induced in NK cells by the exposure to NID1 revealed
a substantial modulation of different molecules and pathways
involved in important biological processes.
Results
Identification of Nidogen-1 as an extracellular ligand for
NKp44 activating NK receptor
Aim of this study was the identification of putative extracel-
lular ligands for NKp44. To this end, we analyzed the
HEK293T cells as possible source of such ligands since these
cells were found to bind NKp44Fc chimeric receptor at their
cell surface. This data suggested that HEK293T cells could
synthesize a putative NKp44-ligand. Importantly, these cells
could be cultured extensively in protein-free medium, thus
facilitating the analysis of proteins released in the culture
supernatant.
Thus, HEK293T cells were cultured in protein-free med-
ium and the supernatants (HEK293T-SN) were collected,
concentrated, and coated on ELISA plates. Direct ELISA was
performed using NKp44Fc, NKp30Fc, NKp46Fc, and DNAM-
1Fc soluble chimeric receptors (Fc molecules). As shown in
Fig. S1A, NKp44Fc strongly bound to HEK293T-SN-coated
wells. Regarding the other Fc molecules tested, only NKp46Fc
showed some reactivity (although significantly weaker than
NKp44Fc), while NKp30Fc and DNAM-1Fc displayed no
binding. These data suggested that NKp44 could recognize
ligand(s) released by HEK293T cells.
To gain further information on such putative NKp44 solu-
ble ligand(s), a metabolic labeling of HEK293T cells was
performed in the presence of azido-sugars. As a result of
this procedure, cells synthesize glycoproteins characterized
by modified glycosylated residues, capable of linking
covalently to biotin, enabling the detection of glycosylated
proteins. The supernatant of labeled HEK293T cells
(HEK293T-SN-biot) was analyzed by ELISA on plates coated
with NKp44Fc or NKp30Fc molecules. As shown in Fig. S1B,
HEK293T-SN-biot reacted with NKp44Fc- (and not with
NKp30Fc-) coated wells, indicating that NKp44Fc can bind
glycosylated protein(s) secreted by HEK293T cells.
The NKp44Fc-reactive glycoprotein(s) were further ana-
lyzed by Western blot. Proteins from concentrated
HEK293T-SN were separated by SDS-PAGE and immuno-
blotted with NKp44Fc. As shown in Fig. S2, NKp44Fc, but
not other Fc molecules analyzed (NKp30Fc, NKp46Fc,
DNAM-1Fc), recognized a band of approximately 180 KDa
under non-reducing conditions.
In order to characterize the high molecular weight glyco-
protein(s) recognized by NKp44Fc, concentrated HEK293T-
SN was resolved by two-dimensional electrophoresis (2-DE)
and analyzed by Western blot with NKp44Fc, NKp46Fc, or
NKp30Fc (Figure 1A–C). Concentrated HEK293T-SN-biot
was subjected to the same procedure and immunoblotted
with Neutravidin-HRP (for the detection of glycoproteins)
(Figure 1D). In parallel, a preparative 2-D gel was stained
with Blue Coomassie to visualize all proteins and excise the
spots of interest (Figure 1E). Following 2-DE and immuno-
blotting, NKp44Fc was found to recognize different proteins
present in HEK293T-SN (Figure 1A). Thus, 27 spots, visua-
lized in NKp44Fc blot, were excised, digested, and analyzed by
high resolution mass spectrometry (Table S1). Thanks to the
comparison with blots stained with NKp46Fc and NKp30Fc
soluble receptors (Figure 1B, 1C) it was possible to subtract
the background and further restrict the analysis to 17 spots.
Finally, by the comparative analysis with the blot stained with
Neutravidin (Figure 1D), we could further select 7 spots
recognized by NKp44Fc and corresponding to glycosylated
proteins. We focused on spot n. 26 because it corresponded
to high MW proteins. Among the proteins identified in this
spot, Nidogen-1 (NID1) displayed a predicted MW compati-
ble with the electrophoretic mobility of the glycoprotein(s)
that had been detected by NKp44Fc in mono-dimensional
SDS-PAGE (i.e. approximately 180 kDa) (see Fig. S2).
The direct and specific binding of NKp44 to NID1 was
confirmed by different experimental evidences. Thus,
immunoprecipitation experiments showed that NKp44Fc
(but not NKp30Fc nor DNAM-1Fc used as controls) was
able to immunoprecipitate NID1 protein from concentrated
HEK293T-SN (Figure 2A). In addition, the ability of
NKp44Fc to bind purified NID1 was investigated by
Western blot. Recombinant human Nidogen-1 (rNID1)
and HEK293T-SN were run in SDS-PAGE in parallel and
immunoblotted with NKp44Fc (and NKp30Fc or
DNAM1Fc as controls). Figure 2B shows that NKp44Fc
was able to recognize both rNID1 and NID1 released
from HEK293T-SN. In contrast, NKp30Fc and DNAM-
1Fc did not display any reactivity. Finally, the interaction
between NKp44 and rNID1 was assessed by ELISA. As
shown in Figure 2C, different concentrations of NKp44Fc
bound to rNID1-coated wells, while NKp30Fc, NKp46Fc,
and DNAM-1Fc did not. This experiment shows that
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soluble NKp44Fc can specifically bind to NID1 also in its
native conformation.
Effect of soluble NID1 on NKp44-mediated cell activation
In order to investigate the potential effect of NID1-NKp44
interaction, we took advantage of a model available in our lab
based on the use of murine Bw5147 (Bw) cell transfectants
expressing either the NKp44/DAP12 receptor complex (Bw-
NKp44) or the chimeric receptor NKp30-CD3ζ (Bw-NKp30).
In this model, cell activation induced by mAb-mediated cross-
linking of NKp44 or NKp30 results in the release in culture
SN of IL-2, which can be measured by ELISA. Since soluble
ligands of different activating receptors have been shown to
interfere with receptor function, we asked whether rNID1
pretreatment of Bw-NKp44 cells had a similar inhibitory
effect. As shown in Figure 3, different rNID1 concentrations
inhibited the NKp44-induced IL-2 production. As control,
Bw-NKp30 cells were also analyzed. A minor inhibition of
NKp30-induced IL-2 production could be detected only at the
highest rNID1 concentration. Since NID1 has been reported
to interact with α3β1 (CD49a/CD29) and αvβ3 (CD51/CD61)
integrins,53,54 we analyzed the expression of CD29, CD49a,
and CD61 in Bw-NKp44 and Bw-NKp30 cells, to rule out
possible biases in the functional data on NID1. As shown in
Fig. S3, expression levels of these integrins on the two Bw cell
transfectants were comparable, indicating that the effects
induced by rNID1 pretreatment were not reasonably influ-
enced by integrin expression.
Next, we asked whether also NID1 released from cells
could inhibit NKp44-mediated cell activation. To this end,
the NID1 construct was transfected in NID1-negative
cells. The culture supernatant of such transfected cells
was assessed in functional assays. The human K562 cell
line was used as recipient, since it does not express NID1
mRNA (Figure 4A). Stable transfection with the NID1
construct resulted in NID1 transcript expression and pro-
tein secretion in cell culture supernatants (Figure 4A, B).
In ELISA, NKp44Fc reacted with K562-NID1-SN and not
with K562-SN (Figure 4C) and in Western blot experi-
ments it specifically reacted with the band corresponding
to NID1 protein, while it didn’t bind to any band of
K562-SN (Figure 4D). In order to investigate the potential
functional consequences of NID1-NKp44 interaction we
used again Bw-NKp44 and Bw-NKp30. Bw-NKp44 cells
were stimulated with anti-NKp44 mAb in the absence or
in the presence of K562-SN or K562-NID1-SN. As shown
in Figure 5A, K562-SN had no effect, while K562-NID1-
SN inhibited NKp44-induced IL-2 release. In contrast,
K562-NID1-SN didn’t induce any inhibitory effect in
Bw-NKp30 cells stimulated via NKp30, as compared to
K562-SN. A similar inhibitory effect on NKp44-induced
Figure 1. Analysis of culture supernatant from HEK293T cells by two-dimensional electrophoresis (2-DE). Concentrated HEK293T-SN was analyzed by two-dimensional
electrophoresis (2-DE). After blotting, membranes were probed with NKp44Fc (A), NKp46Fc (B), or NKp30Fc (C) followed by HRP-conjugated anti-human IgG mAb.
HEK293T-SN-biot was subjected to the same procedure and the membrane was incubated with HRP-conjugated Neutravidin (D). In parallel, HEK293T-SN (600 μg) was
separated by 2-DE and proteins were stained with “blue silver” colloidal Coomassie (E). Numbers indicate the spots selected for mass spectrometry analysis; in panels
(A), (D), and (E) spot 26 is highlighted with a black circle.
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IL-2 production was also detected with culture SN from
NID1-transfected Bw cells (Figs. S4-S5).
We next investigated whether NID1 released by NID1-
expressing cells could exert an inhibitory effect on NKp44-
mediated activation of normal, polyclonal NK cells. To this
end, NK cells isolated from PB were cultured in the pre-
sence of IL-2 to induce the expression of NKp44 (absent on
resting PB-NK cells). NK cells were then stimulated with
anti-NKp44, anti-NKp30, or anti-NKp46 mAbs either in the
absence or in the presence of K562-SN or K562-NID1-SN.
After stimulation, SN of NK cells were collected and ana-
lyzed by ELISA for their IFN-γ content. As shown in
Figure 5B, a significant reduction of NKp44-induced IFN-
γ production was observed in the presence of K562-NID1-
SN, as compared to K562-SN. On the other hand, neither
K562-NID1-SN nor K562-SN inhibited IFN-γ secretion trig-
gered via NKp46 or NKp30. Finally, we investigated
whether NID1-containing SN could affect NKp44-induced
NK cell cytotoxicity. To this end, NK cells were analyzed in
a redirected killing assay either in the absence or in the
presence of K562-SN or K562-NID1-SN. K562-NID1-SN
(but not K562-SN) reduced anti-NKp44-triggered killing of
P815 target cells, while it was ineffective on NKp30- and
NKp46-mediated cytotoxic activity (Figure 5C).
Collectively, these results show that NID1 may interfere
with target cell recognition via NKp44, exerting a regulatory
effect on NKp44-induced NK cell activation.
In view of the recent identification of PDGF-DD as an
extracellular NKp44 ligand, able to induce cytokine produc-
tion by NK cells,52 we investigated whether sNID1 could
inhibit NKp44 triggering induced by this novel ligand. We
first tested this hypothesis in the Bw model, by stimulating
Figure 2. Specific recognition of NID1 by NKp44Fc chimeric receptor. (A) Concentrated HEK293T-SN was immunoprecipitated with the indicated Fc molecules and
analyzed in 7.5% SDS-PAGE under non-reducing conditions; in parallel, concentrated HEK293T-SN was loaded as a positive control. After blotting, the membrane was
probed with mouse anti-NID1 mAb followed by HRP-conjugated anti-mouse IgG mAb. One representative experiment of three is shown. (B) Concentrated HEK293T-
SN and rNID1 were analyzed in SDS-PAGE on a 7.5% polyacrylamide gel under non-reducing conditions and, after blotting, probed with the indicated Fc molecules or
with anti-NID1 mAb, followed by HRP-conjugated anti-human or anti-mouse IgG secondary reagent, respectively. Molecular weight (MW) markers (kDa) are indicated
on the right. One representative experiment of five is shown. (C) ELISA plates were coated with rNID1 and incubated with different concentrations of the indicated Fc
molecules followed by HRP-conjugated anti-human IgG mAb. Graph represents absorbance at 405 nm after normalization to background (nonspecific binding of the
secondary reagent). Data are medians of triplicates ± interquartile range and are the pooled results of three independent experiments. ****p < 0.0001 by two-tailed
Mann-Whitney test.
Figure 3. Effect of rNID1 pretreatment on NKp44-induced IL-2 production in Bw-
NKp44 cells. Bw-NKp44 and Bw-NKp30 cells were left untreated or were pre-
treated with rNID1 at the indicated concentrations for 1 h at 37°C and subse-
quently incubated on anti-NKp44 or anti-NKp30 mAb-coated plates, respectively,
for 20 h. IL-2 release in the SN was evaluated by ELISA. The background (from
GAM-stimulated cells) was subtracted for each value. Data are medians of
duplicates ± interquartile range and are the pooled results of three independent
experiments. **p = 0.0022, ns (not significant) = 0.584, by two-tailed Mann-
Whitney test.
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Figure 4. NKp44Fc recognizes NID1 released by NID1-transfected K562 cells. (A) NID1 mRNA expression was assessed by RT-PCR in wild type or NID1-transfected
K562 cells. Primers specific for β-actin were utilized as positive control. PCR products were run on 1.5% agarose gel and visualized by ethidium bromide staining. One
representative experiment of three is shown. (B, C) ELISA plates were coated with mouse anti-NID1 mAb (B) or with the indicated Fc molecules (C), followed by
incubation with concentrated SN obtained from untransfected or NID1-transfected K562 cells cultured in protein-free medium. NID1 was detected using a goat anti-
NID1 Ab followed by a HRP-conjugated anti-goat IgG Ab. Graphs represent absorbance at 405 nm after normalization to background (nonspecific binding of goat
anti-NID1 + secondary reagent). Data are medians of triplicates ± interquartile range and are the pooled results of three independent experiments. ****p < 0.0001 by
two-tailed Mann-Whitney test. (D) Concentrated SN (30 μl for each sample) derived from K562 cells and the corresponding NID1 transfectants cultured in protein-free
medium were analyzed in SDS-PAGE on a 7.5% polyacrylamide gel; membrane was probed with NKp44Fc molecule or with mouse anti-NID1 mAb followed by the
appropriate HRP-conjugated secondary mAb. MW markers (kDa) are indicated on the right. One representative experiment of two is shown.
Figure 5. Effects of soluble NID1 on NKp44-induced function in Bw-NKp44 cells and human polyclonal NK cells. (A) Bw-NKp44 and Bw-NKp30 cells were incubated on
anti-NKp44 or anti-NKp30 mAb-coated plates, respectively, for 20 h at 37°C in the absence or in the presence of SN derived from untransfected or NID1-transfected
K562 cells. IL-2 release in the SN was evaluated by ELISA. The background (from GAM-stimulated cells) was subtracted for each value. Data are medians of duplicates
± interquartile range and are the pooled results of four independent experiments. ***p = 0.0002, ns = 0.1044, by two-tailed Mann Whitney test. (B) Polyclonal NK cell
lines were incubated with SN derived from wild type or NID1-transfected K562 cells and cultured for 20 h at 37°C on plates coated with anti-NKp44, -NKp30, or
-NKp46 mAbs. IFN-γ release in the SN was evaluated by ELISA. Data are medians of six independent experiments ± interquartile range performed with NK cells from
three donors. *p = 0.0156, ns = 0.1094 (NK + anti-NKp30) and 0.0983 (NK + anti-NKp46) by one-tailed Wilcoxon test. (C) Polyclonal NK cell lines were incubated with
medium or with SN derived from wild type or NID1-transfected K562 cells. After 20 h cells were utilized in a redirected killing assay against the FcγR+ P815 target cell
line in the absence or in the presence of the indicated mAbs (E:T ratios 2:1 and 1:1). Data are medians of duplicates ± interquartile range and are the pooled results
of six experiments performed with NK cells derived from three donors *p = 0.0313 (2:1 ratio) and 0.0156 (1:1 ratio) by one-tailed Wilcoxon test.
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Bw-NKp44 and Bw-NKp30 cells with recombinant (r)PDGF-
DD. As shown in Figure 6A, recombinant PDGF-DD at 250
and 25 ng/ml was able to induce IL-2 production by Bw-
NKp44 cells, while pretreatment of Bw-NKp44 cells with
rNID1 resulted in a dose-dependent inhibition of PDGF-
DD-induced IL-2 release. A similar inhibitory effect was
induced by K562-NID1-SN. As expected, PDGF-DD had no
effects on Bw-NKp30 cells. Next, we assessed the ability of
NID1 to interfere with the PDGF-DD-induced IFN-γ produc-
tion in NK cells. Figure 6B shows that rPDGF-DD could
efficiently stimulate IFN-γ secretion by polyclonal IL-2-acti-
vated NK cells and that this effect was inhibited by K562-
NID1-SN. Taken together, these data highlight the potential
role of NID1 as a decoy NKp44 ligand.
NID1 surface expression and functional effects on NKp44
Having demonstrated that soluble NID1 is able to interfere
with NKp44-mediated NK cell activation, we next asked
whether NID1 could be expressed also at the cell surface
and be recognized as surface-associated molecule with pos-
sible functional outcomes. To this end, we assessed the
cellular expression and distribution of NID1 in HEK293T,
a cell line capable of binding NKp44Fc at its surface (see
above). Thus, HEK293T cells were stained with a NID1-
specific mAb and analyzed by imaging flow cytometry.
This analysis revealed a weak but detectable surface expres-
sion of NID1. Figure 7A shows representative single cells
stained with anti-NID1 mAb, while the histogram profiles in
Figure 7B show the mean fluorescence intensity of all cells
analyzed. The presence of NID1 protein at the cell surface
suggested that it could be accessible for a direct interaction
with NKp44. Thus, we analyzed by flow cytometry the sur-
face expression of NID1 and, in parallel, the reactivity of
NKp44Fc on HEK293T, K562, and K562-NID1 cells. As
shown in Figure 7C, anti-NID1 mAb stained HEK293T and
K562-NID1 cells, but not K562 cells. Consistently, NKp44Fc
bound to HEK293T and K562-NID1 but not to K562 cells.
Comparable results were obtained with Bw-NID1 cell trans-
fectants (Figure 7C). Taken together, these data indicate that
Figure 6. Effects of soluble NID1 on PDGF-DD-induced cytokine production in Bw-NKp44 cells and human polyclonal NK cells. (a) Bw-NKp44 and Bw-NKp30 cells were
left untreated (white bars) or were pre-treated (grey bars) as indicated for 1 h at 37°C and subsequently incubated either on anti-NKp44 or anti-NKp30 mAb-coated
plates, respectively, or stimulated with rPDGF-DD at 250 and 25 ng/ml for 20 h. IL-2 release in the SN was evaluated by ELISA. The background (from GAM-stimulated
or unstimulated cells) was subtracted for each value. Data are medians of duplicates ± interquartile range and are the pooled results of three independent
experiments. *p = 0.0152, **p = 0.0022, ns>0.9999, by two-tailed Mann-Whitney test. (b) Polyclonal NK cell lines were incubated with SN derived from wild type or
NID1-transfected K562 cells and cultured for 20 h at 37°C in the presence of rPDGF-DD at 250 and 50 ng/ml. IFN-γ release in the SN was evaluated by ELISA. Data are
means of six independent experiments ± SEM performed with NK cells from three donors. *p = 0.0156, *p = 0.0325 (K562-SN vs. K562-SN-NID1 PDGF-DD 50 ng/ml),
ns = 0.2188 by one-tailed Wilcoxon test.
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NID1 can be expressed at the cell surface and recognized by
NKp44(Fc) receptor.
On the basis of these results, we further investigated the
possible effect of NID1 expressed at the cell surface on
NKp44-induced NK cell activation. To this end, Bw-NKp44
cells were cultured in the presence of K562 or K562-NID1
cells or in rNID1-coated plates. After 20 h, IL-2 was measured
in culture SN. As shown in Figure 8A, neither K562 nor
K562-NID1 cells could induce increases of IL-2 production
by Bw-NKp44 cells. Similarly, no increments in IL-2 produc-
tion occurred upon culture of Bw-NKp44 in rNID1-coated
plates (Figure 8B). Comparable results were obtained when
rNID1 coating was performed through anti-NID1 (or anti-
His) mAb.
Figure 7. Analysis of NID1 surface expression in HEK293T cell line and in NID1 cell transfectants. (A, B) HEK293T cells were stained with a NID1-specific mAb followed
by PE-conjugated anti-mouse IgG1 mAb. Prior to analysis by Amnis ImageStream, cells were incubated with Hoechst 33342 nuclear dye. NID1 expression on
individual single cells is shown in (A). Data show representative images from one experiment out of three performed. Histograms in (B) represent total intensity of
NID1 immunostaining for HEK293T cells as compared to isotype control. (C) HEK293T, K652, K562-NID1, Bw, and Bw-NID1 cells were stained with a NID1-specific mAb
or with NKp44Fc followed by the appropriate isotype-matched PE-conjugated secondary mAb. Samples were analyzed by flow cytometry. Grey profiles represent
cells stained with anti-NID1 or with NKp44Fc, while white profiles correspond to isotype control. One representative experiment of four is shown.
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We then analyzed whether cell surface NID1 had any effect
on NK cells expressing NKp44 upon activation. To this end,
IL-2-activated polyclonal NK cells were obtained from several
healthy donors and used in functional assays. Since, in NK
cells, NKp44 triggers cytotoxicity, we analyzed the suscept-
ibility to NK cell-mediated killing of NID1+ or NID1− cells in
a cytolytic assay. Because NK cells express different activating
receptors that recognize ligands on human K562 cells, this
assay was performed using murine Bw cell transfectants (see
Fig. S4). As shown in Figure 8C, Bw-NID1 and Bw cells didn’t
display significant differences in their susceptibility to NK-
mediated cytolysis.
We also assessed the possible effect of plastic-bound rNID1
on IFN-γ release from NK cells cultured in rNID1-coated
plates. As shown in Figure 8D, exposure to NID1 failed to
induce significant increments of IFN-γ production by NK
cells.
In order to confirm NKp44 interaction with NID1 exposed
at the cell surface, we performed transient NID1 silencing in
HEK293T cells. SiRNA-mediated silencing resulted in a
reduced presence of NID1 both as surface associated and as
soluble released molecule (Figure 9). Remarkably, NID1 silen-
cing also induced a reduced binding of NKp44Fc to the cell
surface (Figure 9A) and a reduced NKp44Fc reactivity with
the SN derived from NID1-silenced HEK293T cells
(Figure 9B). These results confirm that NKp44Fc is able to
recognize NID1 exposed at the cell surface as well as NID1
released in the extracellular space.
Figure 8. Functional effects of cell surface-associated NID1 or plastic-bound rNID1 in Bw-NKp44 and in NK cells. (A) Bw-NKp44 cells were cultured alone or in the
presence of wild type or NID1-transfected K562 cells for 20 h at 37°C. IL-2 release in the SN was evaluated by ELISA. Data are medians of duplicates ± interquartile
range and are the pooled results of three independent experiments. ns = 0.5714 by two-tailed Mann-Whitney test. (B) Bw-NKp44 cells were incubated on plates
coated with rNID1, anti-NID1 + rNID1, or anti-His + rNID1 for 20 h at 37°C. IL-2 release in the SN was evaluated by ELISA. Data are medians of duplicates ±
interquartile range and are the pooled results of two independent experiments. ns = 0.8286 (−) or ns = 0.6571 (anti-NID1, anti-His) by two-tailed Mann-Whitney test.
(C) Polyclonal NK cell lines were evaluated for their cytolytic activity in a 4-h 51Cr release assay against Bw and Bw-NID1 cells at the indicated E:T ratios. Data are
medians of duplicates ± interquartile range and are the pooled results of fifteen experiments performed with NK cells derived from five donors. *p = 0.0277 by one-
tailed Wilcoxon test. (D) Polyclonal NK cell lines were incubated on plates coated with rNID1 for 20 h at 37°C. IFN-γ release in the SN was evaluated by ELISA. Data are
medians of eight independent experiments ± interquartile range performed with NK cells derived from three donors. ns = 0.2305 by one-tailed Wilcoxon test.
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Effect of NID1 on NK cell proteome
The above data suggest that NID1 exposed at the target cell
surface or bound to a solid support could not significantly
modify the cytokine release or cytotoxicity in NKp44+ cells.
Thus, to gain insight on the possible effects of surface-exposed
NID1 on NK cells, we used a proteomic approach. To this
end, NKp44+ polyclonal NK cell populations expanded from
four healthy donors were cultured for 20 h on plates coated
with rNID1 (NID1) (or w/o coating as control, CTR). In
parallel, NK cells were also cultured on plates coated with
goat anti-mouse IgG (GAM) + anti-NKp44 mAb (NKp44) (or
GAM alone as control, GAM). NK cells were then collected
and lysed; total cell lysates were analyzed by high-resolution
mass spectrometry.
Data processing through the MaxQuant software allowed
the identification of a total of 6903 proteins (of which 5682
were quantified using a Label-Free Quantitation approach).
Most of the proteins (5317) could be identified in all of the
experimental conditions analyzed (i.e. CTR, NID1, GAM, and
NKp44), while few proteins were exclusive of specific condi-
tions (Fig. S6A). An initial analysis of the whole data set (i.e.
without any restriction for statistical significance and fold
change threshold) indicated that both stimuli could modify
the NK cell proteomic profile and could induce concordant
Figure 9. Effect of NID1 silencing on NKp44-NID1 interaction in HEK293T cells and in SN derived from NID1-silenced HEK293T cells. (a) NID1 surface expression and
NKp44Fc reactivity was analyzed in untransfected HEK293T cells and in HEK293T cells transfected with siRNA-NID1 or siRNA-CTR 48 and 72 h after transfection.
Samples were analyzed by flow cytometry. Dotted profiles correspond to isotype control. One representative experiment of three is shown. (b) Western blot analysis
of SN derived from HEK293T cells transfected with siRNA-NID1 or siRNA-CTR. Concentrated SN (30 μg for each sample) derived from untransfected HEK293T cells and
HEK293T transfected with siRNA-NID1 or siRNA-CTR cultured in protein-free medium were analyzed in SDS-PAGE on a 7.5% polyacrylamide gel; membrane was
probed with mouse anti-NID1 mAb or with NKp44Fc molecule followed by the appropriate HRP-conjugated secondary mAb. MW markers (kDa) are indicated on the
right. One representative experiment of three is shown.
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expression changes (i.e. up- or down-regulation) in a sub-
stantial number of proteins (Fig. S6B).
In order to analyze the statistically significant regulated
proteins and to define the possible relationships between
rNID1 and anti-NKp44 stimulation, two volcano plots were
generated from the NID1vsCTR and NKp44vsGAM data
sets, and proteins were selected on the basis of a two-
sample t-test (FDR = 0.05 S0 = 0.1) (Figure 10A, B). By
this selection, 112 proteins resulted modulated by rNID1
(64 up- and 44 down-regulated, as compared to CTR)
(Table S2), and 129 proteins were modulated by anti-
NKp44 mAb (41 up- and 88 down-regulated, as compared
to GAM) (Tab S3). 15 modulated proteins were common to
the two conditions (indicated in red in Figure 10A, B). The
GO analysis indicated that a major fraction of NID1-modu-
lated proteins were involved in the regulation of cell meta-
bolism, but substantial numbers of proteins were also
involved in processes related to cell proliferation, signal
transduction, endo/exocytosis, and immune response, indi-
cating that NID1 stimulation could induce effective func-
tional responses on NK cells (Figure 10C). Interestingly,
NID1- and NKp44-modulated proteins appeared to be
similarly involved in the same biological processes, and
were similarly distributed among the main cellular compo-
nents, with the highest percentage of proteins located in
membrane compartments (Figure 10C, D). In order to
further compare the two stimuli, we drilled down through
the GO biological processes/molecular functions and built a
functional heatmap depicting the quantitative modulation
of the NK cell proteotype in response to NID1 or anti-
NKp44 stimuli (Fig. S7). This analysis indicates that part of
the effects on the modulation of biological processes is
shared by the two stimuli.
On their complex our data suggest that NID1 can bind
NKp44 and induce still unnoticed functional responses on
NK cells. The GO analysis provides substantial information
on these new putative functions, which, however, remain
incompletely defined. In this context, the evaluation of the
proteins modulated by both stimuli may give some hints.
Within this group one of the most up-regulated proteins is
represented by MYSM1 (see Figure 10). Interestingly,
MYSM1 was recently demonstrated to be essential for NK
cell maturation and differentiation,55,56 suggesting that the
NKp44-NID1 interaction may be relevant to these processes
Figure 10. Proteomic analysis of NK cells stimulated with rNID1 or anti-NKp44 mAb. (A, B) Volcano plot representation of differentially expressed proteins. Plots
represent stimulated (rNID1) vs. not stimulated (CTR) NK cells (A) or stimulated (anti-NKp44 mAb) vs. not stimulated (GAM) NK cells (B). Black dots represent proteins
that display both large magnitude fold-changes (x-axis, proteins up-regulated after treatment are shown on the right) as well as high statistical significance (−log10
of P value, y-axis). The black lines show where FDR = 0.05 and s0 = 0.1. Red asterisks represent significantly modulated proteins (with the indicated gene names)
which are present in both datasets. Gray squares represent non statistical significant proteins. (C, D) Gene Ontology (GO) categorization of proteins significantly
modulated by rNID1 and anti-NKp44 mAb stimuli according to biological processes (C) or cellular component (D). On the x axis, the percentage of proteins associated
with the indicated GO terms is shown.
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and play a key role for the homeostasis of the mature NK
cell population.
Discussion
In this study we have identified and characterized a novel
extracellular ligand of the NCR NKp44. Analysis of the culture
supernatant of the NKp44Fc-reactive cell line HEK293T and
the use of 2-DE, combined to high-resolution mass spectro-
metry, revealed NID1 as an NKp44-reactive molecule.
Interaction between NID1 and NKp44 was validated both by
immunoprecipitation and by ELISA experiments, indicating
that NKp44 recognizes NID1 in its native conformation.
Soluble NID1 could down-regulate NKp44-mediated NK cell
activation; in addition, plastic-bound NID1 induced significant
changes in the NK cell proteomic profile, suggesting a possible
effect on various NK cell functions.
NID1 glycoprotein is an essential component of the base-
ment membrane (BM) that plays a role both in BM assembly
and stabilization, and in the adhesion between cells and extra-
cellular matrix (ECM).57,58 Therefore, NKp44-NID1 interac-
tions are likely to occur in tissues, namely in the mucosae,
which contain both NK cells and ILC3, expressing NKp44
receptor.59-61 The role of NKp44 in regulating the function of
these cells has not been clearly defined. Some evidences, how-
ever, indicate that the engagement of NKp44 in ILC3 may
induce TNF-α production and synergize with IL-1, IL-7, and
IL-23 to induce secretion of IL-22 (a cytokine typically pro-
duced by ILC3s).62 In a recent study, the transcriptome analysis
of NKp44-stimulated ILCs revealed a “genome wide regulating
effect”.62 This finding is in line with our present proteomic
study showing that NK cell stimulation both via mAb-mediated
NKp44 cross-linking and by plastic-bound NID1 could induce
significant changes in a relevant number of proteins.
Consistent with the multiple ligand specificities of NKp44
and its ability to mediate different functional responses,
NKp44 cross-linking and NID1-induced stimulation resulted
in protein changes that were only partially overlapping.
However, the GO analysis suggested some common functional
effects induced by the two stimuli. Based on this analysis, NID1
recognition appeared to influence different biological processes
related not only to immunologic functions but also to cell
metabolism, proliferation, and development. In this context,
it is of note that among the limited number of proteins up-
regulated by both stimuli, the highest score was associated with
MYSM1, a molecule that has been proposed to play a role in
NK cell development/maturation.55,56 Thus, the finding that
MYSM1 was strongly induced by both stimulation with rNID1
and mAb-mediated NKp44 cross-linking suggests a new
NKp44-induced cell function and offers clues to study the
role of NKp44-NID1 interaction in the process of NK cell
(and/or ILC) maturation and differentiation.
Functional experiments revealed that soluble NID1 may
play a role as a decoy ligand. Indeed, the addition of rNID1
to cell cultures resulted in inhibition of NKp44-mediated
responses in Bw-NKp44 cells. An inhibitory effect was dis-
played also by soluble NID1 released from cell transfectants.
Importantly, released NID1 could significantly decrease
NKp44-induced IFN-γ secretion (and, marginally,
cytotoxicity) in normal, polyclonal human NK cells.
Remarkably, the NID1-mediated inhibition was specific for
NKp44, although high concentrations of rNID1 had a slight
inhibitory effect also in Bw-NKp30 cells. On the other hand,
the supernatant from NID1-releasing cell transfectants did not
inhibit NKp30 function in Bw-NKp30 cells. In addition, it
could not inhibit NKp30 and NKp46 responses in normal,
polyclonal NK cells (see Figure 5). Finally, rNID1 didn’t react
with NKp30Fc in ELISA (see Figure 2C). Notably, NID1 was
able to inhibit cytokine production triggered not only upon
mAb-mediated NKp44 crosslinking but also by stimulation of
NK cells with the recently characterized NKp44 ligand,
namely PDGF-DD.52 It is conceivable that the release of
NID1 in extracellular fluids may represent a regulatory
mechanism that could act on NKp44+ NK cells at specific
sites or in the blood stream. Notably, recent studies have
highlighted the potential relevance of soluble NID1 as a bio-
marker in different tumors. Li and coworkers reported the
presence of elevated NID1 levels in the serum of ovarian
cancer patients, primarily those with an advanced stage of
the disease.63 Along this line, a high content of a specific
fragment of NID1, derived from its degradation by cathe-
psin-S (CatS) was detected in the serum of NSCLC patients.64
CatS-degraded NID1 was suggested to reflect the loss of BM
integrity, an event typically associated to tumor invasion. On
the other hand, loss of NID1 expression was frequently
detected in human gastrointestinal tumor samples.65 In this
case it was proposed that the loss of NID1 could favor tumor
invasion and metastasis by destabilizing the structure of BM
and loosening the cell-BM interactions. It should be consid-
ered, however, that several reports described a pro-tumoral
and pro-metastatic role for NID1. Thus, NID1 has been
shown to promote tumor cell migration, invasion, and che-
moresistance in ovarian carcinomas via the induction of
Epithelial-Mesenchymal Transition (EMT).66 Another study
revealed a possible NID1 involvement in the acquisition of
migratory and invasive properties by endometrial cancer
cells.67 It has also been shown that NID1 was present at
high levels in the secretome of lung metastases in both breast
cancer and melanoma.68 This study showed that NID1 pro-
moted cancer cell migration, invasion, and metastases in the
lung. Thus, NID1 appears to be released in the extracellular
environment of various tumor types. In this context, the
inhibitory NID1-NKp44 interaction described in our present
study may be regarded as a novel putative suppressive
mechanism exploited by tumors to prevent the NK cell-
mediated attack. Along this line, tumor escape mechanisms
involving the release of soluble ligands have been described
for different activating NK cell receptors. Thus, high levels of
soluble NKG2D or DNAM-1 ligands were detected in serum
of cancer patients and have been associated to advanced stages
of the disease or to poor prognosis.32,33,44 Increased amounts
of soluble B7-H6 were found in sera of melanoma patients
and in the peritoneal fluid of ovarian carcinoma patients.47,49
Soluble BAG6/BAT3 was detected in sera of CLL patients and
could modulate NKp30-mediated cytotoxicity.50 Recently,
Galectin-3 has been described as a soluble molecule released
from tumor cells and capable of inhibiting NKp30-induced
NK cell functions.69 Soluble ligands are often released through
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the action of proteases, as in the case of B7-H6 shedding
caused by ADAM-10 and −17 metalloproteases.47 NID1 is
generally released as a whole molecule. Therefore, it is con-
ceivable that the inhibitory effect on NK cells may be
mediated by the intact molecule. On the other hand, NID1
may be modified in the ECM by the action of extracellular
proteases, such as Cat-S and ADAMTS1 (A Disintegrin and
Metalloproteinase with ThromboSpondin motifs).70 In addi-
tion, NID1 can interact with different BM/ECM proteins
including laminin, collagen type IV, and perlecan.57,58 Thus,
it is possible that the tissue microenvironment and the mole-
cular context may further influence the functional outcome of
the NID1-NKp44 interaction. The ability of NKp44 to recog-
nize NID1 glycoprotein both in denatured and native condi-
tions indicates that NKp44 may bind to a linear epitope. This
observation suggests that NKp44 may recognize also cleaved
NID1 fragments. This issue should be further investigated in
view of the possible targeting of the NKp44-NID1 interaction
in the context of cancer immunotherapy.
Importantly, we show that NID1, besides being released
in the extracellular space, can be also detected at the cell
surface of NID1-releasing cells (see Figure 7). In this
context, it has been reported that NID1 may associate
through the interaction of its RGD sequence with α3β1
or αvβ3 integrins.53,54 Notably, we could detect surface
NID1 on a panel of different NKp44Fc-binding human
tumor cell lines (Figure 11). Although it has been reported
that NID1 up-regulation occurs in several tumor types,
information is still lacking on whether NID1 is associated
to the tumor cell surface. We assessed the possible func-
tional outcome of the interaction between cell surface-
associated NID1 on NKp44+ responding cells. In the Bw-
NKp44 model, no induction of IL-2 production could be
observed. In NKp44+ NK cells, neither induction of IFN-γ
production upon exposure to rNID1-coated plates nor
increase of cytotoxic activity against NID1-expressing tar-
get cells could be detected. On the other hand, as dis-
cussed above, using a proteomic approach, we found that
surface-bound rNID1 could induce changes in proteins
involved in different biological processes. It is conceivable
that such proteomic changes may be induced also by cell
surface-associated NID1.
In conclusion, the characterization of NID1 as a ligand of
NKp44 provides new interesting hints to extend our knowledge
on the NK cell biology. Future investigations of the functional
effects of NID1 in different molecular contexts (i.e. associated
with ECM proteins or modified by ECM enzymes) may help to
understand the mechanisms regulating NK cell (and ILC3) func-
tion in tissues. In addition, studies based on proteomic data may
lead to the definition of new functional roles of NKp44 receptor
(and, consequently, of NK cells) in different biological processes.
Taken together, our present study may offer clues and open new
opportunities for a more effective exploitation of NK cells for
therapeutic purposes, especially (but not exclusively) in the
immunotherapy of solid tumors.
Methods
Antibodies
The following monoclonal antibodies (mAbs), produced in
our laboratory, were used in this study: BAB281 (IgG1, anti-
NKp46), AZ20 (IgG1, anti-NKp30) and Z231 (IgG1, anti-
NKp44). The following commercial antibodies were also
used: mouse anti-Nidogen-1 mAb (IgG1, clone 302117,
R&D, MAB2570) and goat anti-NID1 polyclonal Ab (R&D,
AF2570); mouse anti-NKp46 (IgG1, clone 29A1.4.9, Miltenyi
Biotec, 130-095-118); hamster anti-mouse CD29-PE (IgGλ,
clone HMβ1-1, Miltenyi Biotec, 130-102-994); hamster anti-
mouse CD61-PE (IgGκ, clone 2C.9.G2, Miltenyi Biotec,
130-102-851); human anti-mouse CD49a-PE (IgG1, clone
REA493, Miltenyi Biotec, 130-107-632); goat anti-human
IgG Horseradish Peroxidase (HRP)-conjugated mAb,
(Southern Biotech, 2040-05), goat anti-mouse Ig HRP-conju-
gated mAb (Southern Biotech, 1031-05), mouse anti-goat IgG
HRP-conjugated mAb (Southern Biotech, 6164-05), and goat
anti-mouse IgG1 phycoerythrin (PE)-conjugated mAb
(Southern Biotech, 1070-09); goat anti-human IgG PE-conju-
gated mAb (Jackson ImmunoResearch, 109-116-170); rabbit
polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) Ab (ThermoFisher, PA1-16780); mouse anti-His
mAb (IgG1, clone BMG-His-1, Roche Diagnostics, 1 922 416).
Cell lines
The following cell lines, purchased from American Type
Culture Collection (ATCC), were used in this study:
HEK293T (human embryonic kidney), K562 (human erythro-
leukemia), Bw1547 (Bw, murine thymoma), SH-SY-5Y
Figure 11. Analysis of NID1 surface expression and NKp44Fc reactivity on a panel of human cell lines. The indicated cell lines (SH-SY-5Y neuroblastoma; A172
glioblastoma; C-32 melanoma; A2774 ovarian adenocarcinoma; JEG-3 placental choriocarcinoma; A549 lung carcinoma) were stained with a NID1-specific mAb or
with NKp44Fc followed by the appropriate isotype-matched PE-conjugated secondary mAb. Samples were analyzed by flow cytometry. Grey profiles represent cells
stained with anti-NID1 or with NKp44Fc, while white profiles correspond to isotype control. One representative experiment of three is shown.
e1470730-12 S. GAGGERO ET AL.
(human neuroblastoma), A172 (human glioblastoma), C-32
(human melanoma), A2774 (human ovarian adenocarci-
noma), JEG-3 (human placental choriocarcinoma), A549
(human lung carcinoma). Cell lines were maintained either
in DMEM (HEK293T) or RPMI1640 medium supplemented
with 10% (v/v) fetal calf serum (FCS), L-glutamine, and anti-
biotics (penicillin and streptomycin). For some experiments,
HEK293T and K562 cell lines were also cultured in protein-
free CD medium (ThermoFisher, 11279023). Stably trans-
fected K562 cells were selected and cultured in the presence
of G418 sulphate (Calbiochem, 345810) at the final concen-
tration of 1.2 mg/ml. All cell lines were periodically tested and
were mycoplasma free.
Preparation of soluble chimeric receptors
NKp44Fc, NKp30Fc, and NKp46Fc soluble receptors were
prepared as previously described.71 Briefly, the sequences
coding for the extracellular portion of the different receptors
were subcloned in the pRB1-2B4Fcmut vector (kindly pro-
vided by Dr. M Falco, Ist. G. Gaslini, Genova) in frame with
the sequence coding for the human IgG1 portion, that was
mutagenized in order to obtain a mutated Fc that does not
bind to Fc receptors. These constructs were transfected into
HEK293 cell line utilizing JetPEI (Polyplus, 101-10) following
manufacturer’s instructions; after 48–72 h, cells were selected
with 0,5 mg/ml G418 sulphate, in order to obtain stably
transfected cells, and subcloned by limiting dilution. SN
were collected from cell clones cultured either in DMEM/
10% Ultra-low IgG FCS (ThermoFisher) or in Ex-CELL
ACF CHO medium (Sigma, C5467) and the soluble Fc mole-
cules were purified by affinity chromatography utilizing
Protein A Sepharose 4 Fast Flow (G-Biosciences, 786-283).
Purified recombinant proteins were checked by SDS-PAGE
followed by silver staining and by ELISA utilizing mAbs
specific for the different receptors.
Preparation of cell culture supernatants
Cell culture supernatants (SN) were obtained from wild type
or transfected K562 or Bw cells. After 48–72 h culture in
medium supplemented with 1% (v/v) FCS or in protein-free
CD medium, SN were collected and utilized for subsequent
experiments either as they were or following concentration
(up to 30-fold) with Amicon Ultracel-10K (Millipore,
UFC901024). Protein content in SN derived from culture in
protein-free CD medium was determined using Bradford
Protein Assay (Bio-Rad, 5000006).
Metabolic labeling
HEK293T cells were cultured in protein-free CD medium in
the presence of ManAz (N-azidoacetylmannosamine-tetraacy-
lated) (ThermoFisher, 88904) at the final concentration of 40
μM. After 72 h, SN was collected, concentrated (up to 24-fold)
with Amicon Ultracel-10K, and incubated with Biotin-PEG3-
Phosphine (200 μM final concentration, ThermoFisher,
88901) O/N at room temperature, in order to label secreted
glycoproteins containing azido-sugars. Labeled SN was
dialyzed in PBS using D-Tube Dialyzer Maxi, MWCO 6–8
kDa (Novagen, 71509-3).
Enzyme-linked immunosorbent assay (ELISA)
Direct ELISA: 100 μl of concentrated SN derived from
HEK293T cells cultured in protein-free CD medium were
coated on ELISA plates O/N at 4°C. Next, wells were saturated
with PBS/3% (w/v) bovine serum albumin (BSA) for 3 h at r.
t., washed in PBS, and incubated with Fc molecules at differ-
ent concentrations ranging from 2.5 to 80 μg/ml or with 1 μg/
ml anti-NID1 mAb followed by the appropriate HRP-conju-
gated secondary reagent. Similar experiments were carried out
on ELISA plates coated with 5 μg/ml recombinant human
Nidogen-1 (rNID1) (R&D, 2570-ND-050) in PBS.
Indirect (sandwich) ELISA: a similar procedure was
applied. Briefly, ELISA plates were coated with Fc molecules
(5 μg/ml in PBS), saturated, and incubated with 100 µl
HEK293T-SN-biot followed by HRP-conjugated Streptavidin
(Southern Biotech, 7100-05). Alternatively, ELISA plates were
coated with mouse anti-NID1 mAb or Fc molecules (5 μg/ml
in PBS), saturated, and incubated with 100 µl SN derived from
wild type or NID1-transfected K562 or Bw cells cultured in
medium with 1% (v/v) FCS or in protein-free CD medium.
Next, a polyclonal goat anti-NID1 Ab was added, followed by
a HRP-conjugated anti-goat Ig mAb.
In all experiments a final incubation with the HRP sub-
strate ABTS (2,2ʹ-azino-di-(3-ethylbenzthiazoline sulfonic
acid) (Roche Diagnostics, 102 946) was performed. The col-
orimetric signal was measured with a microplate reader
(TECAN Sunrise) at an optical density (OD) of 405 nm.
Western blot analysis
Samples (6–28 μg SN obtained in protein-free medium, 30 μl
SN obtained in medium/1% FCS, 160 ng rND1) were run on
7,5% or 10% polyacrylamide gels under non-reducing condi-
tions and transferred to Immobilon-P PVDF membranes
(Millipore, IPVH00010). For some experiments, gels were pre-
pared with 7.5% TGX Stain-Free Acrylamide Solutions (Bio-
Rad, 161-0181). Membranes were blocked with 5% BSA in
Tris-buffered-saline containing 0.05% Tween-20 (TBS-T) and
probed with anti-NID1 mAb, a rabbit polyclonal anti-GAPDH
Ab, or Fc molecules (7 μg/ml) followed by the appropriate
HRP-conjugated secondary reagent. The SuperSignal West
Pico Chemiluminescent Substrate (ThermoFisher, 34,080)
was used for detection. Images were acquired with ChemiDoc
Touch Imaging System (Bio-Rad) and analyzed with Image Lab
software (Bio-Rad).
Two-dimensional electrophoresis (2-DE) and western blot
Concentrated HEK293T-SN and HEK293T-SN-biot (300 μg
for Western blot and 600 μg for preparative gels) were solubi-
lized in the reduction/alkylation solution containing 8 M urea,
4% CHAPS, 5 mM tributylphosphine (TBP), 20 mM iodoace-
tamide (IAA), 40 mM Tris, and 0.1 mM EDTA for 1 h. To
prevent over-alkylation during the isoelectro focusing (IEF)
step, excess of IAA was neutralized by adding an equimolar
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amount of DTT. Finally, samples were dissolved in the focus-
ing/re-hydration solution, i.e. 7 M urea, 2 M thiourea, 4%
CHAPS, and 15 mM dithioerythritol (DTE) and a 0.6% (v/v)
carrier ampholyte cocktail, containing 40% of the pH 3.5–10
and 60% of the pH 4–8 intervals (BDH Biochemical, 44430 2F)
and loaded onto home-made non-linear pH 3–10 strips.72 After
IEF runs, the strips were equilibrated in 6 MUrea, 50 mMTris-
HCl pH 8.8, 2% (w/v) SDS, 30% (v/v) glycerol, and traces of
bromophenol blue; the proteins were separated using a SDS-
PAGE (T% 8–16) and transferred onto nitrocellulose mem-
branes (Protran BA85, Whatman, 10402588) with a semidry
system. The membranes were saturated with 3% w/v polyvinyl-
pyrrolidone (PVP) in TBS and incubated overnight separately
with NKp44Fc, NKp30Fc, or NKp46Fc in 3% w/v BSA in TBS-
Tween 0.15% v/v (TBS-T). Membranes were then rinsed in
TBS-T and incubated with anti-human IgG HRP-conjugated
mAb. HEK293T-SN-biot was subjected to the same procedure
and immunoblotted with Neutravidin-HRP (ThermoFisher,
31001). For preparative experiments, SDS-gels were stained
with “blue silver” colloidal Coomassie.73 Images were digita-
lized using ChemiDoc Touch (Bio-Rad) and analyzed with
PDQuest software (Bio-Rad).
2-DE spot identification
Spots excised from 2D-PAGE were fully discolored and
digested with trypsin. All mass spectrometric measurements
were performed using a LTQ linear ion trap mass spectro-
meter (Thermo Electron) coupled to a HPLC Surveyor
(Thermo Electron) equipped with a Jupiter C18 column
250 mm × 1 mm (Phenomenex). Protein identification was
performed using SEQUEST software and searched against a
Human protein database. Peptide MS/MS assignments were
filtered following very high stringent criteria: Xcorr ≥1.9 for
the singly charged ions, Xcorr ≥2.2 for doubly charged ions,
Xcorr ≥3.7 for triply charged ions, peptide probability ≤0.01,
delta Cn ≥0.1 and Rsp ≤4.26.
Immunoprecipitation
Immunoprecipitation experiments were carried out using
12 µg NKp44Fc, NKp30Fc, or DNAM-1Fc molecules linked
to 50 μl Dynabeads Protein G (ThermoFisher, 10003D) and
incubated O/N at 4°C with 400 µl concentrated HEK293T SN
(corresponding to 500 µg proteins). Samples were eluted using
non-reducing sample buffer (10% glycerol, 2% SDS, 62.5 mM
Tris-HCl pH 6.8, 0.01% bromophenol blue) for 5ʹ at 60°C and
subsequently analyzed by SDS-PAGE using TGX Stain-Free
Acrylamide Solutions; membrane was probed with mouse
anti-NID1 mAb followed by HRP-conjugated anti-mouse
Ig mAb.
RT-PCR analysis
Total RNA was extracted using RNAeasy Mini Kit (Qiagen,
74,104) from the following cells: K562, K562-NID1, Bw, Bw-
NID1. Oligo(dT)-primed cDNA was prepared by standard tech-
nique using a Transcriptor First Strand cDNA Synthesis Kit
(Roche Diagnostics, 04379012001) following manufacturer’s
instructions. Amplifications were performed for 30 cycles utiliz-
ing Platinum TAQ DNA Polymerase (ThermoFisher, 10966034)
with an annealing T of 58°C (β-actin) or 62°C (NID1). Primers
used were: β-actin for 5ʹ ACTCCATCATGAAGTGTGACG and
β-actin rev 5ʹ CATACTCCTGCTTGCTGATCC; NID1 for 5ʹ
CTCCATTGGGCCTGTGAGG and NID1 rev 5ʹ AGACACGG
GGGC GTCATC. PCR products (249 bp fragment for β-actin
and 795 bp forNID1) were separated by electrophoresis on a 1.5%
(w/v) agarose gel and visualized by ethidium bromide staining.
Stable cell transfectants
K562 cell line was transfected with pcDNA3.1-NID1 construct
(Geneart, ThermoFisher) using JetPEI following manufac-
turer’s instructions. After 72 h cells were cultured in medium
containing 1.2 mg/ml G418 sulphate. At the end of the selec-
tion period, surviving cells were sub-cloned by limiting
dilution.
Bw-NID1 cells were prepared by retrovirus gene transfer.
NID1 ORF cDNA was sub-cloned in pMXs-IG (IRES-GFP)
retrovirus vector (kindly provided by Dr. Kitamura, Tokyo,
Japan). The pMXs-IG-NID1 construct was transiently trans-
fected into Plat-E packaging cell line in order to generate viral
particles that were used to infect Bw cells. NID1-positive cells
were sorted according to GFP expression; subsequently,
NID1-positive cells were sub-cloned by limiting dilution.
Bw-NKp44/DAP12 cells (Bw-NKp44) were obtained by a
similar approach, utilizing pMXS-IG vector, in which
NKp44 ORF and DAP12 ORF cDNAs were sub-cloned in
the two available cloning sites (GFP-encoding sequence was
replaced by DAP12 ORF cDNA). NKp44-expressing cells
were sorted and sub-cloned by limiting dilution. Bw-NKp30-
CD3ζ cells (Bw-NKp30), expressing a chimeric molecule com-
posed of the extracellular region of NKp30 fused to murine
CD3ζ, were kindly provided by Eric Vivier (Marseille,
France), and were sorted and sub-cloned by limiting dilution.
For the recovery of SN from K562 and BW cells and
transfectants, cell culture was carried out either in RPMI/1%
FCS or in protein-free CD medium and SN was collected after
48–72 h. In the latter case, SN were concentrated up to 10-
fold using Amicon Ultracel-10K.
Functional assays on Bw cells
1 × 105 Bw cells were pre-treated 1 h at 37°C with 20 or 7.5
μg/ml rNID1 or with 100 μl SN obtained from wild type or
transfected K562 and Bw cells cultured in RPMI/1% FCS,
and subsequently plated on 96-well cell culture plates
(1 × 105 cells/well) coated with 5 μg/ml goat anti-mouse
IgG (GAM, MP Cappel, 55481) alone or with GAM plus
anti-NKp44 or -NKp30 mAbs. Alternatively, pretreated cells
were stimulated with rPDGF-DD (R&D, 1159-SB) at 250
and 25 ng/ml. For co-culture experiments, Bw cells were
pre-incubated 1 h at 37°C with wild type or NID1-trans-
fected K562 and Bw cells at an effector/target (E/T) ratio of
1:1 and then transferred on mAb-coated plates. In other
experiments, Bw-NKp44 cells were incubated on plates in
which rNID1 was coated either directly or through anti-
NID1 or anti-His mAbs. For all these assays, after 20 h at
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37°C, SN were collected and analyzed for their IL-2 content
by ELISA using the Mouse IL-2 ELISA Ready-SET-Go
(eBioscience, BMS88-7024-77) according to manufacturer’s
instructions. Each sample was run in duplicate.
Generation of polyclonal NK cell lines
NK cells were derived from healthy donors. Approval was
obtained from the ethical committee of IRCCS Ospedale
Policlinico San Martino (39/2012) of Genova (Italy), and
informed consent was provided according to the Declaration of
Helsinki. NK cells were purified from peripheral blood using the
RosetteSep™ NK Cell Enrichment Cocktail (StemCell
Technologies, 15025). Those populations displaying more than
95% of CD56+CD3−CD14− NK cells were selected. Polyclonal
NK cell lines were obtained by culturing purified NK cells at
appropriate dilutions on irradiated feeder cells in the presence of
100 U/mL rhIL-2 (Proleukin, Novartis) and 1,5 ng/mL phytohe-
magglutinin (PHA, Gibco Ltd, 10576-015) in round-bottomed
96-well microtiter plates. After 3/4 weeks of culture the expanded
NK cells were used for NK cell stimulation experiments.
Functional assays on NK cells
Evaluation of NK cell-mediated cytotoxicity against Bw and
Bw-NID-1 transfected cells or against the P815 FcγR+ murine
cell line (redirected killing assay) was done in a 4-h 51Cr-
release test. In the redirected killing assay mAbs were added at
the final concentration of 1.25 μg/ml (anti-NKp30 and anti-
NKp46 mAbs) or 0.5 μg/ml (anti-NKp44 mAb) (appropriate
concentration was determined after titration to induce specific
functional response in NK cells). When indicated, K562-SN or
K562-NID1-SN was added to NK cells (50% v/v) 1h before the
onset of the test.
For the IFN-γ secretion assay, NK cells (10 × 104/well)
were cultured overnight in 96-well microtiter plates pre-
coated with GAM either in the absence or in the presence of
anti-NKp44, -NKp30, -NKp46 mAbs. Alternatively, NK cells
were stimulated with rPDGF-DD at 250 and 50 ng/ml. When
indicated, K562-SN or K562-NID1-SN was added at the onset
of culture. The culture SN were then collected and analyzed
for the presence of IFN-γ using the IFN gamma Human
ELISA Kit (ThermoFisher, EHIFNG).
Imaging flow cytometry
HEK293T cells were incubated with anti-NID1mAb followed by
PE-conjugated anti-IgG1 mAb. Prior to analysis, cells were
stained with the nuclear dye Hoechst 33342 (ThermoFisher,
62249) (1:1000 dilution). Cells were acquired with a 12 channel
MultiMag system ImageStreamX Mark II imaging flow cyt-
ometer (IFC) (Merck) using INSPIRE acquisition software
(Amnis Corporation). Three ImageStream channels were used:
channel 1 for the brightfield, channel 3 for NID1-PE (excited by
a 488-nm laser), channel 7 for Hoechst 33342 (excited by a 405-
nm laser). In order to collect only on focus-single-cells, we first
restricted our attention on the brightfield (BF) parameters ana-
lysis. Single cells were selected using a biparametric dot plot
representing BF aspect ratio (i.e. width/height) versus BF cell
area then, by mean of the BF gradient RMS (root mean square),
which measures the sharpness quality of an image, we gated only
on focus cells. For each staining condition, 4,000 raw images
were collected using a 40x objective. To avoid spectral overlaps,
single-color compensation controls (500 cells each) were gath-
ered and a compensation matrix was generated. The raw image
files were then analyzed using IDEAS 6.0.3 software (Amnis
Corporation) setting compensation on the basis of the calculated
matrix. To verify the correspondence between data derived from
traditional cytometry and IFC, we compared NID expression
with its negative control (i.e. cells labeled only with secondary
PE-conjugated mAb) by mean of their MFI (mean fluorescence
intensity). To grant a better visualization of these data, we
merged the two files.
Flow cytometry
Cells were incubated with the primary mAbs or Fc molecules
(20 μg/ml) for 30 minutes at 4°C, washed, and stained with
the appropriate PE- isotype-matched secondary mAbs for 30ʹ
at 4°C. Bw-NKp44 and Bw-NKp30 cells were incubated with
PE-conjugated anti-integrin mAbs for 30ʹ at 4°C. All samples
were analyzed using a FACSCalibur flow cytometer and
CellQuest Pro software (BD Biosciences).
Silencing experiments
NID1 expression was transiently silenced in HEK293T cells by
siRNA transfection using iBONi siRNA 4-duplexes Plus (Riboxx
Life Sciences). In particular, the following siRNA were used:
siRNA-NID1 (ID4811_4): Sense 5ʹ-UAAACCAUCUUGUCCA
CGCCCCC-3ʹ, Antisense 5ʹ-GGGGGCGUGGACAAGAUGGU
UUA-3ʹ; siRNA-CTR (iBONi Negative Control-N3): Sense 5ʹ-
ACAACAUUCAUAUAGCUGCCCCC-3ʹ, Antisense 5ʹ-GGGG
GCAGCUAUAUGAAUGUUGU-3ʹ.
siRNA (300 nM) were introduced in HEK293T cells by
Nucleofector technology (Lonza) using Amaxa Cell Line
Nucleofector Kit V (Lonza, VACA-1003); after 48 and 72 h
cells were analyzed by flow cytometry with anti-NID1 mAb
and NKp44Fc followed by appropriate PE-conjugated second-
ary reagents. For the analysis of SN derived from NID1-
silenced cells, siRNA (50 nM) were transfected in HEK293T
cells with Interferin (Polyplus, 409-10) following manufac-
turer’s instructions. Cells were then cultured in CD medium;
after 72 h SN were collected, concentrated, and analyzed by
Western blot with anti-NID1 mAb and NKp44Fc followed by
appropriate HRP-conjugated secondary reagents.
Proteomic analysis of polyclonal NK cell populations
Polyclonal IL-2-activated NK cells derived from four different
healthy donors were cultured for 20 h at 37°C in FCS- and IL-
2-deprived medium in the absence or in the presence of
rNID1 (20 μg/ml) directly coated on the plate or of anti-
NKp44 mAb coated via GAM. Next, for subsequent proteo-
mic analysis, cells were processed by in-StageTip (iST)
method.74 Briefly, the pellets were lysed, reduced, alkylated
in a single step using a buffer containing 2% (w/v) SDC
(sodium deoxycholate), 10 mM TCEP (Tris(2-carboxyethyl)
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phosphine hydrochloride), 40 mM CAA (chloroacetamide),
100 mM Tris HCl pH 8.0, and loaded into StageTip. The
lysates were diluted with 25 mM Tris pH 8.5 containing
1 µg of trypsin. Samples were acidified with 100 µl of 1% (v/
v) TFA (Trifluoroacetic Acid) and washed three times with
0.2% (v/v) TFA. Elutions were performed with 60 µl of 5% (v/
v) ammonium hydroxide, 80% (v/v) ACN.
Samples were loaded from the sample loop directly into a
75-μm ID × 50 cm 2 μm, 100 Å C18 column mounted in the
thermostated column compartment and the peptides were
separated with increasing organic solvent at a flow rate of
250 nl/min using a non-linear gradient of 5–45% solution B
(80% CAN and 20% H2O, 5% DMSO, 0.1% FA) in 180 min.
Eluting peptides were analyzed using an Orbitrap Fusion
Tribrid mass spectrometer (ThermoFisher Scientific).
Orbitrap detection was used for both MS1 and MS2 measure-
ments at resolving powers of 120 K and 30 K (at m/z 200),
respectively. Data dependent MS/MS analysis was performed
in top speed mode with a 2 sec. cycle time, during which
precursors detected within the range of m/z 375 − 1500 were
selected for activation in order of abundance. Quadrupole
isolation with a 1.8 m/z isolation window was used, and
dynamic exclusion was enabled for 30s. Automatic gain con-
trol targets were 2.5 × 105 for MS1 and 5 × 104 for MS2, with
50 and 54 ms maximum injection times, respectively. The
signal intensity threshold for MS2 was 1 × 104. HCD was
performed using 28% normalized collision energy. One
microscan was used for both MS1 and MS2 events.
MaxQuant software,75 version 1.6.0.1, was used to process
the raw data, setting a false discovery rate (FDR) of 0.01 for
the identification of proteins, peptides and PSM (peptide-
spectrum match), a minimum length of 6 amino acids for
peptide identification was required. Andromeda engine,
incorporated into MaxQuant software, was used to search
MS/MS spectra against Uniprot human database (release
UP000005640_9606 February 2017). In the processing the
variable modifications are Acetyl (Protein N-Term)
Oxidation (M), Deamidation (NQ); on the contrary the
Carbamidomethyl (C) was selected as fixed modification.
The intensity values were extracted and statistically evaluated
using the ProteinGroup Table and Perseus software.
Algorithm MaxLFQ was chosen for the protein quantification
with the activated option ‘match between runs’ to reduce the
number of the missing proteins.
Statistical analyses
Data were analyzed using GraphPad Prism 6, R, or Perseus
software. Details of statistical analysis for each experiment are
indicated in the corresponding figure legend.
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